Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease
暂无分享,去创建一个
W. Hiatt | J. Lepore | E. Hu | P. Qin | L. Demopoulos | Zixing Fang | K. Mahar | Eric J. Olson | T. Haws | T. Bauer